News | May 25, 2021
Astrazeneca Pharma India Q4FY21 net profit up at Rs 27.27 Cr
The company has reported total income of Rs.826.40 crores for FY 2020-21
The company has reported total income of Rs.826.40 crores for FY 2020-21
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Subscribe To Our Newsletter & Stay Updated
